April 19, 2026 —
Three pioneers in gene therapy—Jean Bennett, Albert Maguire, and Katherine High—have been awarded the prestigious Breakthrough Prize in Life Sciences for their role in developing Luxturna, the first gene therapy approved in the United States. The award, often referred to as the “Oscars of science,” recognizes their decades-long effort to bring adeno-associated virus (AAV)-based gene therapy from concept to clinical reality.
Luxturna, now owned by Roche, utilizes an engineered AAV vector to deliver a functional copy of the RPE65 gene to retinal cells, partially restoring vision in patients with inherited retinal dystrophy. The therapy’s success represents a landmark validation of AAV-mediated gene delivery, demonstrating that genetic diseases can be treated at their root by replacing defective genes.
The journey to approval was far from straightforward. Early efforts in gene therapy faced major setbacks, including safety concerns and limited durability of gene expression. The team explored multiple viral platforms before identifying AAV as a promising vector due to its ability to target neuronal cells and sustain gene expression in retinal tissue. Preclinical success in animal models, including the restoration of vision in blind dogs, provided compelling evidence that the approach could translate to humans.
However, the field encountered significant challenges in the late 1990s and early 2000s, particularly following the Jesse Gelsinger case, which led to increased regulatory scrutiny and a sharp decline in funding. Despite these obstacles, the researchers persisted, eventually advancing Luxturna into clinical trials and demonstrating meaningful improvements in functional vision, particularly in low-light conditions—an outcome not captured by traditional visual acuity endpoints.
The therapy received FDA approval in 2017, marking a turning point for the gene therapy field. Yet, despite this breakthrough, the broader translation of gene therapy into additional approved treatments has progressed more slowly than anticipated. Challenges remain in clinical development, including selecting appropriate endpoints, managing costs, and addressing the complexities of treating ultra-rare diseases with small patient populations.
The scientists emphasized that while the underlying science has never been stronger, the field must overcome economic and regulatory hurdles to fully realize its potential. AAV-based gene therapies, in particular, continue to hold promise across a wide range of diseases, from inherited blindness to systemic genetic disorders, but scalability, pricing, and long-term durability remain key considerations.
Looking ahead, the awardees expressed optimism that genetic medicine will become a foundational pillar of modern therapeutics, akin to monoclonal antibodies today. However, they stressed that continued collaboration across academia, industry, and regulatory bodies will be essential to accelerate innovation and expand access to these transformative therapies.
